Trial reportCancer medicine2021
Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first-line treatment of metastatic castration-resistant prostate cancer.
Trial report in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Assessment of the therapeutic efficacy of [European journal of nuclear medicine and molecular imaging · 2025Pooled it
- Curcumin as a complementary treatment in oncological therapy: a systematic review.European journal of clinical pharmacology · 2025Pooled it
- The Association Between Anti-Neoplastic Effects of Curcumin and Urogenital Cancers: A Systematic Review.BioMed research international · 2024Pooled it
- Curcumin as a Synergy Amplifier in Cancer Therapy.Pharmaceutics · 2026Review
- Therapeutic potentials of curcumin in prostate cancer: a comprehensive review of pathways and clinical prospects.Prostate international · 2026Review
- The role of curcumin in modulating circular RNAs and long non-coding RNAs in cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Triggering Pyroptosis in Cancer.Biomolecules · 2025Review
- Antioxidant Senotherapy by Natural Compounds: A Beneficial Partner in Cancer Treatment.Antioxidants (Basel, Switzerland) · 2025Review
- Plant-derived extracellular vesicles: an alternative and complementary therapeutic approach for genitourinary tumors.Frontiers in cell and developmental biology · 2025Review
- Navigating the redox landscape: reactive oxygen species in regulation of cell cycle.Redox report : communications in free radical research · 2024Review
- Semisynthetic phytochemicals in cancer treatment: a medicinal chemistry perspective.RSC medicinal chemistry · 2024Review
- Curcumin's effect in advanced and metastatic breast cancer patients treated with first or second-line docetaxel: A randomized trial.Health science reports · 2024Article
- Anti-Cancer Properties of Two Intravenously Administrable Curcumin Formulations as Evaluated in the 3D Patient-Derived Cancer Spheroid Model.International journal of molecular sciences · 2024Article
- Innovative Delivery Systems for Curcumin: Exploring Nanosized and Conventional Formulations.Pharmaceutics · 2024Review
- A phase I study of docetaxel plus synthetic lycopene in metastatic prostate cancer patients.Clinical and translational medicine · 2024Article
- Curcumin can improve spinal cord injury by inhibiting DNA methylation.Molecular and cellular biochemistry · 2024Article
- Co-Delivery of Docetaxel and Curcumin Functionalized Mixed Micelles for the Treatment of Drug-Resistant Breast Cancer by Oral Administration.International journal of nanomedicine · 2024Article
- Obesity, dietary interventions and microbiome alterations in the development and progression of prostate cancer.Frontiers in immunology · 2024Review
- Chinese herbal medicines for prostate cancer therapy: From experimental research to clinical practice.Chinese herbal medicines · 2023Review
- Reports of Plant-Derived Nanoparticles for Prostate Cancer Therapy.Plants (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetastatic castration-resistant prostate cancer (mCRPC) patients have a poor prognosis, and curcumin is known to have antineoplastic properties. On the basis of previous phase I and phase II studies, we investigated whether the association of curcumin with docetaxel could improve prognosis among mCRPC patients.
methodsA total of 50 mCRPC patients (included from June 2014 to July 2016) treated with docetaxel in association with oral curcumin (6 g/d for 7 days every 3 weeks) versus placebo were included in this double-blind, randomized, phase II study. The primary endpoint was to evaluate the time to progression. Among the secondary endpoints, compliance, overall survival, prostate-specific antigen (PSA) response, safety, curcumin absorption, and quality of life were investigated. An interim analysis was planned in the modified intention-to-treat population with data at 6 months (22 patients per arm).
resultsDespite good compliance and a verified absorption of curcumin, no difference was shown for our primary endpoint: progression-free survival (PFS) between the placebo and curcumin groups was, respectively, 5.3 months versus 3.7 months, p = 0.75. Similarly, no difference was observed for the secondary objectives: PSA response rate (p = 0.88), overall survival (p = 0.50), and quality of life (p = 0.49 and p = 0.47).
conclusionEven though our previous studies and data in the literature seemed to support an association between curcumin and cancer therapies in order to improve patient outcome and prognosis, the results from this interim analysis clearly showed that adding curcumin to mCRPC patients' treatment strategies was not efficacious. The study was discontinued on the grounds of futility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.